These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36631162)

  • 1. Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma.
    Sun M; Cao Y; Okada R; Reyes-González JM; Stack HG; Qin H; Li N; Seibert C; Kelly MC; Ruppin E; Ho M; Thiele CJ; Nguyen R
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36631162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.
    Wu H; Zhang G; Liu Z; Liu W; Wang X; Zhao Y
    Cytotherapy; 2024 Nov; 26(11):1308-1319. PubMed ID: 38904586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
    Heitzeneder S; Bosse KR; Zhu Z; Zhelev D; Majzner RG; Radosevich MT; Dhingra S; Sotillo E; Buongervino S; Pascual-Pasto G; Garrigan E; Xu P; Huang J; Salzer B; Delaidelli A; Raman S; Cui H; Martinez B; Bornheimer SJ; Sahaf B; Alag A; Fetahu IS; Hasselblatt M; Parker KR; Anbunathan H; Hwang J; Huang M; Sakamoto K; Lacayo NJ; Klysz DD; Theruvath J; Vilches-Moure JG; Satpathy AT; Chang HY; Lehner M; Taschner-Mandl S; Julien JP; Sorensen PH; Dimitrov DS; Maris JM; Mackall CL
    Cancer Cell; 2022 Jan; 40(1):53-69.e9. PubMed ID: 34971569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
    Li N; Torres MB; Spetz MR; Wang R; Peng L; Tian M; Dower CM; Nguyen R; Sun M; Tai CH; de Val N; Cachau R; Wu X; Hewitt SM; Kaplan RN; Khan J; St Croix B; Thiele CJ; Ho M
    Cell Rep Med; 2021 Jun; 2(6):100297. PubMed ID: 34195677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma.
    Pascual-Pasto G; McIntyre B; Hines MG; Giudice AM; Garcia-Gerique L; Hoffmann J; Mishra P; Matlaga S; Lombardi S; Shraim R; Schürch PM; Yarmarkovich M; Hofmann TJ; Alikarami F; Martinez D; Tsang M; Gil-de-Gómez L; Spear TT; Bernt KM; Wolpaw AJ; Dimitrov DS; Li W; Bosse KR
    Nat Commun; 2024 Aug; 15(1):7141. PubMed ID: 39164224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
    Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
    Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
    Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors.
    Li D; Liang T; Hutchins LE; Wolfarth AA; Ferrando-Martinez S; Lee BH; Ho M
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39043602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells.
    Pascual-Pasto G; McIntyre B; Giudice AM; Alikarami F; Morrissey A; Matlaga S; Hofmann TJ; Burgueño V; Harvey K; Martinez D; Shah AC; Foster JB; Pogoriler J; Eagle RC; Carcaboso AM; Shields CL; Leahey AM; Bosse KR
    Clin Cancer Res; 2024 Aug; 30(16):3578-3591. PubMed ID: 38864848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
    Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
    Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma.
    Tian M; Cheuk AT; Wei JS; Abdelmaksoud A; Chou HC; Milewski D; Kelly MC; Song YK; Dower CM; Li N; Qin H; Kim YY; Wu JT; Wen X; Benzaoui M; Masih KE; Wu X; Zhang Z; Badr S; Taylor N; Croix BS; Ho M; Khan J
    J Clin Invest; 2022 Aug; 132(16):. PubMed ID: 35852863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
    Andersch L; Radke J; Klaus A; Schwiebert S; Winkler A; Schumann E; Grunewald L; Zirngibl F; Flemmig C; Jensen MC; Rossig C; Joussen A; Henssen A; Eggert A; Schulte JH; Künkele A
    BMC Cancer; 2019 Sep; 19(1):895. PubMed ID: 31500597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
    Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
    Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
    Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS
    Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
    Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
    J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.